Sun Pharma Q1 results: Sun Pharmaceutical Industries on Thursday reported 40.2% year-on-year (YoY) consolidated net profit growth at ₹2,835.62 crore for the first quarter of FY25. The company’s net profit in the year-ago quarter was ₹2,022.54 crore.
Drug major Sun Pharma’s revenue from operations in Q1FY25 grew 6% year-on-year to ₹12,652.7 crore from ₹11,940.84 crore.
US formulation sales fell 1% to $466 million and accounted for more than 31.1% of total consolidated sales. Formulation sales in India grew by 16.4% to ₹4,144.5 crore and were approximately 33.1% of total consolidated sales.
Sun Pharma said the pharma company’s formulation sales in emerging markets stood at $284 million for Q1FY25, a growth of 8.8% and accounted for 18.9% of total consolidated sales.
During the quarter ending June 2024, outbound sales of API were at ₹494.6 crore, down 8.3%.
“Sun has recently achieved several milestones with the approval of Lexalvi in the US, the filing of Nidlegi in Europe and the completion of the acquisition of Taro minority shares. Dilip Shanghvi, Chairman and Managing Director, Sun Pharmaceutical Industries, said, “These steps further enhance our innovative and innovative business offerings and will help us better serve patients.
At the operational level, earnings before interest, taxes, depreciation and amortization (EBITDA) during the June 2024 quarter rose 8.3% to ₹3,331.7 crore from ₹3,607 crore, while EBITDA margin expanded 60 basis points (bps) to 28.5% from 27.9. Done. %, Year after year.
The company’s R&D investment in Q1FY25 stood at ₹794 crore compared to ₹679.6 crore for Q1FY24.
